• Home
    • StockRanks™
    • Platform
        • Research & Discuss
        • Editorial & Community
        • Learn & Improve
        • Webinars & Masterclasses
        • Stockopedia Academy
    • Reviews
    • Pricing
    Get startedLog in
    SectorsHealthcareBiotechnology & Medical ResearchRecursion Pharmaceuticals
    Picture of Recursion Pharmaceuticals logo

    RXRX — Recursion Pharmaceuticals News Story

    $4.160.000.00%
    us flag iconLast trade - 00:00
    HealthcareSpeculativeMid CapNeutral
    • Market Cap
      $2.23bn
    • Enterprise Value
      $1.70bn
    • Revenue
      $74.68m
    • Quality
    • Value
    • Momentum
    • StockRank™
    • StockReport™
    • Accounts
      • Balance sheet
      • Income statement
      • Cashflow statement
      • Dividend summary
    • News
    • RXRX Dividends
    StockReport™
    Balance sheet
    Income statement
    Cashflow
    News
    RXRX Dividends
    All News

    Brief: Recursion Pharmaceuticals Q1 Net Income USD -91.4 Million

    Picture of Recursion Pharmaceuticals logoRecursion Pharmaceuticals
    09/05/2024 21:01
    May 09 (Reuters) - Recursion Pharmaceuticals Q1 operating revenue USD 13.8
    million
    

    Recent news on Recursion Pharmaceuticals

    See all news
    • Brief: Tempus And Recursion Extend Existing Data License Agreement And Enter New License Agreement For Recursion’S RNA Foundation Model

      21/09/2026 14:24
    • Brief: Recursion Pharmaceuticals Enters Amendment To Master Agreement With Tempus On Sept 15, 2026 - SEC Filing

      21/09/2026 14:08
    • Recursion Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary

      05/08/2026 14:30
    • Recursion Pharmaceuticals Q2 revenue misses estimates, cuts 2026 expense outlook

      05/08/2026 11:42
    • Brief: Recursion Pharmaceuticals Q2 Operating Revenue USD 7.303 Million Vs. IBES Estimate USD 11.9 Million

      05/08/2026 11:31

    Company

    • About us
    • Careers
    • Product Guide

    Our Coverage

    • Countries
    • Sectors
    • Ratios

    Top Stocks

    • UK Stocks
    • Australian Stocks
    • US Stocks

    Legals

    • Privacy Policy
    • Terms & Conditions
    • Disclaimer & FSG
    • Cookies
    Trustpilot
    Select a country/region:


    © Stockopedia 2026, Refinitiv, Share Data Services.

    *Past performance is no indicator of future performance, and testimonials are provided by third parties for informational purposes only and are not intended and should not be taken to be financial product advice. Performance returns are based on hypothetical scenarios and do not represent an actual investment.

    This site cannot substitute for professional investment advice or independent factual verification. To use Stockopedia, you must accept our Terms of use, Privacy and Disclaimer & FSG. All services are provided by Stockopedia Ltd, United Kingdom (company number 06367267). For Australian users: Stockopedia Ltd, ABN 39 757 874 670 is a Corporate Authorised Representative of Daylight Financial Group Pty Ltd ABN 77 633 984 773, AFSL 521404.